3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Interventions
Specimen Handling
195
Magnetic Resonance Spectroscopy
148
Biopsy
117
pembrolizumab
91
Carboplatin
85
Cisplatin
77
Nivolumab
71
Cyclophosphamide
69
Paclitaxel
64
Gemcitabine
52
Radiotherapy
48
Bevacizumab
44
durvalumab
41
Dexamethasone
37
Fluorouracil
35
Doxorubicin
35
venetoclax
34
Pemetrexed
33
Capecitabine
33
olaparib
32
Rituximab
31
Oxaliplatin
31
Injections
31
atezolizumab
30
Etoposide
29
fludarabine
28
Radiation
28
Prednisone
28
Lenalidomide
27
Docetaxel
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histamine Antagonists
×
30 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled